Cellectar Biosciences, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The company is a clinical-stage oncology biopharmaceutical developer using its phospholipid drug conjugate (PDC) platform. Its lead candidate, iopofosine I 131, remains investigational; the company reported no revenue for the periods presented.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $28.2 million | $19.2 million |
| General and administrative expense | $10.7 million | $9.6 million |
| Operating loss | $39.0 million | $28.8 million |
| Net loss | $38.0 million | $28.6 million |
| Net loss per share, basic and diluted | $3.11 | $4.05 |
| Cash used in operating activities | $32.4 million | $25.2 million |
| Cash and cash equivalents at year-end | $9.6 million | $19.9 million |
- R&D expense rose 47%, chiefly due to increased manufacturing and clinical-trial costs; G&A rose 12%.
- Year-end current assets were $10.5 million and current liabilities were $12.9 million. Total liabilities were $13.4 million, primarily accounts payable and accrued liabilities, warrant liabilities, and lease liabilities. No conventional borrowing balance is identified in the provided financial statements.
- The company reported an accumulated deficit of $217.5 million and negative stockholders’ equity of $1.4 million. It has incurred recurring losses and expects further operating losses.
- In September 2023, a preferred-stock and warrant financing generated $24.5 million gross proceeds and approximately $22.2 million net proceeds. After year-end, Tranche A warrant exercises generated $44.1 million gross and approximately $42.8 million net proceeds in January 2024; further warrant exercises in January and February generated approximately $1.1 million net.
- Management estimated cash, including the January 2024 warrant proceeds, would fund basic budgeted operations into the fourth quarter of 2024. Additional financing is needed to execute plans beyond that period. The auditor and management cited substantial doubt about the company’s ability to continue as a going concern within one year; the statements contain no adjustments for that uncertainty.
Business and material developments
- CLOVER-WaM, a pivotal Phase 2 study of iopofosine in relapsed/refractory Waldenstrom’s macroglobulinemia, completed enrollment in Q4 2023. Topline results announced in January 2024—after the fiscal year—showed a 61% major response rate in the 45-patient modified intent-to-treat population, exceeding the prespecified 20% hurdle; overall response was 75.6% among 41 efficacy-evaluable patients. Median duration of response was not reached, and 76% remained progression-free at median follow-up of eight months. These are company-reported topline results, not a marketing approval.
- In that study, Grade 3 or higher treatment-related thrombocytopenia, neutropenia, and anemia occurred in 55%, 37%, and 26%, respectively. The company reported no treatment-related discontinuations or deaths in the study. Across its broader iopofosine experience, it disclosed that fatalities resulting from infection have occurred.
- Phase 2b evaluation in relapsed/refractory multiple myeloma and central nervous system lymphoma and a Phase 1b pediatric high-grade glioma study were ongoing. Other programs include preclinical alpha-emitter and non-radiotherapeutic PDC candidates, plus partnered assets.
Outlook, risks, and other notable items
- The company’s plans depend on obtaining additional capital through equity or debt financing, strategic transactions, or other sources. Financing may dilute shareholders or require the company to reduce, delay, or partner its development programs.
- AtomVie is the sole supplier of iopofosine drug product for ongoing research and clinical studies. A supply disruption, regulatory issue, or difficulty transferring manufacturing could delay trials or development.
- Clinical development and regulatory approval remain uncertain; early or topline trial results may not predict later outcomes. Iopofosine’s common toxicities include cytopenias, and the filing identifies infection-related fatalities in clinical experience.
- As of December 31, 2023, management concluded internal control over financial reporting was ineffective due to three material weaknesses: valuation of Level 3 instruments, stock-based compensation accounting, and limited finance staff and inadequate segregation of duties/access controls. Management reported remediation efforts underway; no material misstatements or historical financial-statement changes were identified.
- The company reported 20 full-time employees, relied on outsourced research and manufacturing, and identified Nasdaq continued-listing compliance and further share dilution as risks. The September 2023 financing included warrants that could convert into substantial additional common shares.
Important facts for investors to verify
- Current cash runway and whether additional financing will be required before or after the projected Q4 2024 runway end.
- Final and follow-up CLOVER-WaM results, including durability, safety, and any FDA feedback on the registration path.
- Progress, enrollment, and results in the multiple myeloma, CNS lymphoma, and pediatric glioma programs.
- Manufacturing continuity with AtomVie and availability of qualified alternative supply capacity.
- Remediation and testing of the three reported material weaknesses, and the potential dilution from preferred stock, warrants, and equity awards.